Abstract: A process is provided in which the resulting Fe-tCDTA contrast agent has a reduced osmolality. The process according to the invention comprises the following steps: a) preparing an aqueous solution of tCDTA and FeO(OH), tCDTA and FeO(OH) being present in a molar ratio of from 1:1 to 1:1.4; b) b.1) adjusting a pH of the aqueous solution to between pH 2.5 and pH 4.5 by adding a base, preferably meglumine, and separating the precipitate; or b.2) precipitating the Fe-tCDTA contrast agent from the aqueous solution by adding acetone, separating the precipitate, and preparing an aqueous solution from the precipitate; and c) adjusting a pH of the aqueous solution to between pH 6.5 and pH 8.0 by adding a base, preferably meglumine, and separating the precipitated FeO(OH).

Abstract: A process is provided in which the resulting Fe-tCDTA contrast agent has a reduced osmolality. The process according to the invention comprises the following steps: a) preparing an aqueous solution of tCDTA and FeO(OH), tCDTA and FeO(OH) being present in a molar ratio of from 1:1 to 1:1.4; b) b.1) adjusting a pH of the aqueous solution to between pH 2.5 and pH 4.5 by adding a base, preferably meglumine, and separating the precipitate; or b.2) precipitating the Fe-tCDTA contrast agent from the aqueous solution by adding acetone, separating the precipitate, and preparing an aqueous solution from the precipitate; and c) adjusting a pH of the aqueous solution to between pH 6.5 and pH 8.0 by adding a base, preferably meglumine, and separating the precipitated FeO(OH).

Abstract: The invention includes a substance based on nanocrystalline maghemite having a crystal size of between 0.5 and 4 nm, which is defined by a proportion of divalent iron ions less than five percent by weight of the total iron, and the transport of sodium and simultaneously phosphate in the gastrointestinal wall from the gastrointestinal contents into the bloodstream is reduced and thus can improve the imbalance of electrolyte and water and mineral balances of patients having impaired renal function when used orally in combination with suitable pharmaceutical adjuvants.

Abstract: The invention includes a substance based on nanocrystalline maghemite having a crystal size of between 0.5 and 4 nm, which is defined by a proportion of divalent iron ions less than five percent by weight of the total iron, and the transport of sodium and simultaneously phosphate in the gastrointestinal wall from the gastrointestinal contents into the bloodstream is reduced and thus can improve the imbalance of electrolyte and water and mineral balances of patients having impaired renal function when used orally in combination with suitable pharmaceutical adjuvants.

Abstract: The invention concerns a vehicle wheel, comprising a body of a plastics material and at least one adapter for fastening the body to a wheel mounting, the at least one adapter having at least one protuberance which engages in a recess in the body, or, if multiple adapters are used, at least one adapter is formed such that it engages in a recess of the body over its full surface area, the adapter being arranged in such a way that, after assembly of the body on the wheel mounting, the adapter is positioned between the body and the wheel mounting, or the adapter being arranged in such a way that the body is positioned between the wheel mounting and the adapter, so that the adapter lies on the outside of the body after assembly.

Abstract: The present invention relates to magnetic particle dispersions comprising coated monocrystalline and/or polycrystalline single nanoparticles of iron oxides and nano-particulate aggregates (multi-core particles) thereof with improved nonlinear magnetization behavior and improved heating properties in alternating magnetic fields. When measured in a magnetic particle spectrometer (MPS) the particle dispersions show a pronounced overtone structure, especially in the higher harmonics, which surpasses all previously known particle systems many times over. Therefore, the dispersions are especially useful for applications such as MPI (magnetic particle imaging). In addition, the new particle dispersions are suitable for treatment of iron deficiency anemia and for applications in therapeutic hyperthermia, particularly passive partial-body hyperthermia or cell tracking and magnetic resonance imaging (MRI).